Servier Appoints David K. Lee to Executive Committee
Improving the lives of our patients
We work tirelessly to deliver meaningful therapeutics for the patients we serve.
Servier Appoints David K. Lee to Executive Committee
Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors
Servier Partners With Local Cancer Center to Support Research Graduate Students in the Boston Area